Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: dwight martin who wrote (27007)	12/24/1998 4:46:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

I missed the Nightline show, but saw some excerpts on Nightline. Looks like an expansion of the LA Times report. Yesterday, the LA Times reported a legislative inquiry and Nightline indicated that the NIH was going to look at conflict of interest regulations in advisory committee. Could get very messy. Looks like bad press for Rezulin is accelerating. Should push WLA to step up R&D. That could be a plus for LGND, as well as LLY's progress on Actos. SBH will be moving Avandia pretty aggressively also. Details linked to Ligand diabetes page at biocognizance.com